Evidence map›Paper›PMID 41492460›Full record

ArticleJournal of pharmaceutical analysis2025

Metabolomics-driven elucidation of the synergistic therapeutic mechanism of a novel SGLT-2/PPAR-γ dual receptor supramolecular system for treatment diabetes and obesity.

Saisai Ren, Han Hao, Wei Guo, Mo Zhang, Honglin Feng, Jing Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saisai RenSchool of Pharmaceutical Sciences, Hebei Key Laboratory of Innovative Drug Development and Evaluation, National Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang, 050017, China.
Han HaoSchool of Pharmaceutical Sciences, Hebei Key Laboratory of Innovative Drug Development and Evaluation, National Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang, 050017, China.
Wei GuoSchool of Pharmaceutical Sciences, Hebei Key Laboratory of Innovative Drug Development and Evaluation, National Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang, 050017, China.
Mo ZhangSchool of Pharmaceutical Sciences, Hebei Key Laboratory of Innovative Drug Development and Evaluation, National Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang, 050017, China.
Honglin FengDepartment of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Jing WangSchool of Pharmaceutical Sciences, Hebei Key Laboratory of Innovative Drug Development and Evaluation, National Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang, 050017, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A supramolecular system of active pharmaceutical ingredients (APIs) can modify the physicochemical properties and enhance the synergistic efficacy of their components; however, the relevant underlying mechanisms

Indexed as

DagliflozinDiabetesMetabolomicsObesityPioglitazoneSupramolecular system

Identifiers

PMID41492460
PMCPMC12765261

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.